COMMUNIQUÉS West-GlobeNewswire

-
Congress Passes Bills Making Major Investments in Alzheimer’s
23/03/2024 -
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
22/03/2024 -
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
22/03/2024 -
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
22/03/2024 -
Vistin Pharma ASA: Mandatory notification of trade
22/03/2024 -
Nutra Pharma Corp. Reaches Settlement with SEC
22/03/2024 -
IBEX Reports Results for the Second Quarter and Six Months Ended January 31, 2024
22/03/2024 -
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22/03/2024 -
Alvotech Announces Increase in Number of Own Shares
22/03/2024 -
Alvotech Announces Increase in Number of Own Shares
22/03/2024 -
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
22/03/2024 -
Veru Reschedules Annual Meeting of Shareholders
22/03/2024 -
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
22/03/2024 -
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023
22/03/2024 -
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22/03/2024 -
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
22/03/2024 -
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
22/03/2024 -
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
22/03/2024 -
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
22/03/2024
Pages